Visit of Cormorant Pharmaceuticals

David Waugh (Participant)

Activity: Other activity typesHosting a delegation or group


Hosted a specific visit from Swedish Biotech company who are keen to develop a collaborative programme with my research group focused on our mutual interest of IL-8/CXCR2 biology in the pathogenesis of cancer. Cormorant have an IND with an anti-IL-8 antibody currently undergoing phase I safety trials at the National Cancer Institute in Bethesda, USA. Undertaking will be to contribute to the research strategy of future phase II trials, through conduct of pre-clinical research in specific disease models.
Period28 Aug 2015
Held atCormorant Pharmaceuticals, Sweden